Horizon Pharma goes public at $9

Horizon Pharma ($HZNP) went public this morning, pricing 5.5 million shares at $9 a share. That's a little below the $10 to $12 range that it had hoped for, but not too bad considering some of the biotech IPOs that have floated at far bigger discounts so far this year. Horizon has also granted the underwriters a 30-day option to purchase up to an additional 825,000 shares at the initial public offering price to cover overallotments. Release

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."